AxoGen Reports 2017 Fourth Quarter and Full Year Financial Results

AxoGen (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerves, today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2017.

As quoted in the press release:

• Revenue of $17.0 million, up 49% compared to $11.4 million in the fourth quarter of 2016
• Gross margin of 84.6% compared to 84.0% in the fourth quarter of 2016
• Adjusted EBITDA loss of $531,000 compared to adjusted EBITDA loss of $2.2 million in Q4 2016
• Announced expanded application in Breast Reconstruction Neurotization
• Adjusted net loss for the fourth quarter of 2017 was $2.5 million, or $0.07 per share, compared with adjusted net loss of $3.2 million, or $0.10 per share, in the fourth quarter of 2016
• Raised $15.6 million in net proceeds through a public offering of common stock on November 20

Click here to read the full press release.